Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Incyte

Status and phase

Terminated

Phase 2

Conditions

NSCLC (Non-small Cell Lung Carcinoma)

Treatments

Drug: Placebo

Drug: Pemetrexed

Drug: Cisplatin

Drug: Ruxolitinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02119650

INCB 18424-266

Details and patient eligibility

About

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Full description

The study consisted of an open-label, safety run-in (consisting of 1 to 4 cohorts of 9 participants each), to confirm the safety of ruxolitinib in combination with pemetrexed/cisplatin in participants with nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent. Participants in the safety run-in received open-label ruxolitinib and pemetrexed and cisplatin.

In the second part of the study, participants enrolled and randomized and received pemetrexed and cisplatin (open-label) and either ruxolitinib or placebo in a blinded manner. The dose of ruxolitinib administered was determined from the data produced in the safety run-in phase.

Treatment consisted of repeating 21-day cycles. Participants received infusions of pemetrexed and cisplatin on Day 1 of each cycle and ruxolitinib/placebo was self-administered during the entire cycle. Maintenance therapy with ruxolitinib or placebo in combination with pemetrexed, based on the original treatment assignment, was allowed for participants eligible for maintenance therapy.

Enrollment

76 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).
Radiographically measurable or evaluable disease.
Life expectancy of at least 12 weeks.
Tumor without activating driver mutations for which there is available therapy (eg, tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).
An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
- Criteria:
  - C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1
  - C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.

Exclusion criteria

Squamous or mixed histology (eg, adenosquamous) NSCLC
Previous systemic therapy for advanced or metastatic disease.
Known active central nervous system (CNS) metastases.
Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including New York Heart Association functional classification of 3, or arrhythmia requiring treatment.
Uncontrolled concomitant medical conditions, including, but not limited to, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric diseases.